FDA Official Foresees Reduced Biosimilar Data Burden
Deep Product Understanding Expected To Move Regulators To Reduce Clinical Data Requirements
New guidance from UK's MHRA saying comparative clinical efficacy studies typically will not be needed is a start, but other regulators may need a few years before adopting similar rules.
